Our cohort policies for approved drugs can be found below (further policies will added once they are approved).

  Abiraterone + Cabazitaxel for Prostate Cancer

  Abraxane (Paclitaxel albumin) for Breast Cancer

  Alemtuzumab for B-cell Chronic Lymphocytic Leukaemia (CLL)

  Azacitidine in Chronic Myelomonocytic Leukaemia 2, with myeloproliferative disorder

  Azacitidine for Myelodysplastic Syndrome - This drug was originally approved for funding by the ICDF panel in October 2010.  It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund.  The relevant NICE guidance is available here. The WM CDF will continue to fund the use of Azacitadine in line with the CDF policy for three months from the publication of the NICE Technology Appraisal; the appropriate PCT will be expected to provide funding for Azacitadine, in line with NICE recommendations, from 1 July 2011.

  Bendamustine in CLL - This drug was originally approved for funding by the ICDF panel in November 2010.  It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund.  The relevant NICE guidance is available here. The WM CDF will continue to fund the use of Bendamustine in CLL in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate PCT will be expected to provide funding for Bendamustine, in line with NICE recommendations, from 1 June 2011.

  Bendamustine monotherapy or combined with Rituximab for relapsed CLL 

  Bendamustine + Rituximab for 1st Line CLL 

  Bendamustine for Indolent non-Hodgkin’s lymphoma (as monotherapy following Rituximab)

  Bevacizumab for Advanced Colorectal Cancer

  Bevacizumab for triple neg Breast Cancer

  Bevacizumab for Advanced Breast Cancer (following Paclitaxel or Docetaxel)

   Bevacizumab for Ovarian Cancer

  Bortezomib for Multiple Myeloma with renal failure

  Cetuximab + Panitumumab for Advanced Colorectal Cancer

  Cetuximab for recurrent and/or metastatic Squamous Cell Carcinoma of the head and neck

  Eribulin for Advanced Breast Cancer

  Everolimus for Renal Cell Cancer

  FOLFOX for Pancreatic Cancer

  Fulvestrant for Advanced Breast Cancer

  Imatinib adjuvant for Gastrointestinal Stromal Tumour (GIST)

  Imatinib for Locally Advanced or Metastatic Chordoma

  Imatinib for Melanoma

  Imatinib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) 

  Ipilimumab for Melanoma

  Lapatinib for Advanced Breast Cancer

  Lenalidomide for Myelodysplasia

  Ofatumumab for Chronic Lymphocytic Leukaemia (CLL)

  Pazopanib for Renal Cancer

  Pemetrexed Maintenance for Non-Squamous Non-Small Cell Lung Cancer

Rituximab for Follicular Lymphoma - This drug was originally approved for funding by the ICDF panel in December 2010.  It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund.  The relevant NICE guidance is available here. The WM CDF will continue to fund the use of Rituximab in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate PCT will be expected to provide funding for Rituximab, in line with NICE recommendations, from 1 October 2011.

  Rituximab + Chemotherapy for 1st Line Mantle Cell Lymphoma

  Sorafenib for Hepatocellular Cancer

  Sunitinib + Everolimus for Pancreatic Neuroendocrine Tumours

  Temsirolimus for Renal Carcinoma

  Trastuzumab for Gastric Cancer

 The following drugs were not approved for funding:

  Azacitidine in Chronic Myelomonocytic Leukaemia

  Bendamustine for Multiple Myeloma

  Bevacizumab for Recurrent High Grade Glioma

  Cetuximab for Advanced Colorectal Cancer

  Vinflunine for Transitional Cell Carcinoma of the Urothelium

  Yttrium for Neuroendocrine Tumours

The application process for the West Midlands Cancer Drug Fund is explained here.

If you have any general queries regarding the process you can either email wm.cancerdrugs@nhs.net or call Janice Cunningham at West Midlands Strategic Commissioning Team (WMSCT) offices on telephone number: 0121 695 2374.